09R Stock Overview

A clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. More details

09R fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Highly volatile share price over the past 3 months compared to the German market

Earnings are forecast to decline by an average of 28.8% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Skye Bioscience, Inc. Competitors

2invest

XTRA:2INV

€69.5m

4SC

DB:VSC

€21.8m

Heidelberg Pharma

XTRA:HPHA

€148.2m

co.don

XTRA:CNW

€6.5m

Price History & Performance

Summary of share price highs, lows and changes for Skye Bioscience
Historical stock prices
Current Share Price	US$1.41
52 Week High	US$3.49
52 Week Low	US$0.89
Beta	1.75
1 Month Change	41.00%
3 Month Change	-59.60%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-50.12%

Recent updates

Shareholder Returns

	09R	DE Biotechs	DE Market
7D	-20.3%	0.8%	0.7%
1Y	n/a	-11.0%	13.8%

Return vs Industry: Insufficient data to determine how 09R performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 09R performed against the German Market.

Price Volatility

Is 09R's price volatile compared to industry and market?
09R volatility
09R Average Weekly Movement	40.5%
Biotechs Industry Average Movement	5.8%
Market Average Movement	6.4%
10% most volatile stocks in DE Market	12.9%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: 09R's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 09R's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	16	Punit Dhillon	skyebioscience.com

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.

Skye Bioscience, Inc. Fundamentals Summary

How do Skye Bioscience's earnings and revenue compare to its market cap?
09R fundamental statistics
Market cap	€50.56m
Earnings (TTM)	-€29.44m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.9x

P/E Ratio

Is 09R overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
09R income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$32.65m
Earnings	-US$32.65m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-1.05
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 09R perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/12 21:47
End of Day Share Price	2025/05/12 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Skye Bioscience, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kristen Kluska	Cantor Fitzgerald & Co.
Jonathan Wolleben	Citizens JMP Securities, LLC
Gum-Ming Lowe	Craig-Hallum Capital Group LLC

Skye Bioscience DB:09R Stock Report